

About the Editors

Peiman Hematti, M.D., is an Associate Professor of Medicine, Pediatrics, Surgery, and Biomedical Engineering at the University of Wisconsin-Madison, School of Medicine and Public Health. He obtained his M.D. degree from Tehran University, School of Medicine, and completed residencies in Internal Medicine and Pediatrics at the Cleveland Clinic Foundation and a clinical and research fellowship in Hematology at the National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, Maryland. He joined UW-Madison in 2004 as a bone marrow transplant Physician and soon became the Director of the Clinical Hematopoietic Cell Processing Laboratory and Director of Bone Marrow Collection, Apheresis and Processing Center, at the University of Wisconsin Hospital and Clinics. His clinical research interests are in the use of mesenchymal stromal cells for treatment of graft-versus-host disease and other immune dysregulation disorders, use of novel cellular therapies for hematological malignancies, and use of bone marrow stem cells in regenerative medicine. His laboratory research focuses on investigating the immunomodulatory properties of mesenchymal stromal cells with a focus on their interactions with macrophages. He is collaborating with many investigators from a wide range of disciplines at the local, national, and international levels studying the potential of mesenchymal stromal cells in many different in vitro and in vivo preclinical models with the ultimate goal of using these cells in clinical trials. He is the Coprincipal Investigator of the UW-Madison “Production Assistance for Cellular Therapies” (PACT) award from NHLBI-NIH and 2012 Chair of PACT Education Steering Committee. He has been recently selected to serve as the American Society of Hematology Representative to the AABB Cellular Therapies Standards Program Unit. Dr. Hematti is on the editorial board of several journals including *Experimental Hematology* and *Cytotherapy*. He has numerous manuscripts and book chapters published in the field of mesenchymal stromal cells.

Armand Keating, M.D., FRCP(C), is a Professor of Medicine, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation, and a Professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, Toronto, Canada. He is also the Director of the Cell Therapy Program and

the Orsino Cell Therapy Translational Research Laboratory at Princess Margaret Hospital. He obtained the M.D. degree from the University of Ottawa, completed residencies in Internal Medicine and Hematology at the University of Toronto and a research fellowship at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle. He was a Cancer Research Scientist of the National Cancer Institute of Canada for 10 years and upon his return to Toronto, established the largest stem cell transplant program in Canada. He was the Chief of Medical Services and Head, Department of Medical Oncology and Hematology at Princess Margaret Hospital/Ontario Cancer Institute in Toronto for a decade. More recently, he established the largest and most active cell therapy program in Canada involving local, national, and international collaborators. He became President of the American Society of Hematology (ASH) in 2012. He is a past President of the American Society for Blood and Marrow Transplantation and was Chair of the Steering Committee for Cell-Based Therapy of the National Heart, Lung, and Blood Institute, US National Institutes of Health. He also chaired the Medical and Scientific Committee of the Leukemia and Lymphoma Society and was a Member of its Board of Directors for 8 years. He is on numerous editorial boards of scholarly journals, and is a Coeditor of Bone Marrow Transplantation and Associate Editor of *Biology of Blood and Marrow Transplantation*. Dr. Keating's clinical and research interests focus on anticancer cell therapy, blood and marrow transplantation, leukemia, lymphoma, and cell-based tissue regeneration. He has conducted laboratory, translational and clinical research in cell therapy, on normal and leukemic hematopoiesis, and on the biology and clinical application of mesenchymal stromal cells. He has authored over 350 publications.

Index

A

- ACI. *See* Autologous chondrocyte implantation (ACI)
- Acute kidney injury (AKI)
 - clinical trials
 - case-matched historical controls, 613
 - clinical setting and enrollment criteria, 610–611
 - objectives, 611
 - preoperative risk factors, 611–613
 - study design and methods, 610
 - definition and classification, 607
 - high risk, 606–607
 - pathophysiology, 607–608
 - phase I clinical trial, 617
 - preclinical studies, 608–609
 - preliminary efficacy
 - CKD, 616
 - hospital stay, 616, 618
 - RIFLE and AKIN, 615
 - safety, 613–614
 - treatment, 608
 - uremic multisystem complications, 606
- Acute kidney injury network (AKIN), 607
- Acute lung injury (ALI)
 - dendritic cells, T and B cells, 568
 - ex vivo perfused human lung preparation
 - allogeneic human MSCs, 573
 - alveolar fluid, 570, 571
 - KGF, 571
 - lung endothelial permeability, 570
 - paracrine factors, 572
 - Pseudomonas aeruginosa*, 572
 - therapeutic properties, 572, 573
 - multiple preclinical models, 575
 - preclinical animal and cell studies, 568–569
 - treatment, 574
- Acute neurological disorders
 - spinal cord injury (*see* Spinal cord injury (SCI))
 - stroke (*see* Stroke)
 - traumatic brain injury (*see* Traumatic brain injury (TBI))
- Acute respiratory distress syndrome (ARDS), 574
- Adipose tissue, 202–203
- Adipose tissue-derived stromal/stem cells (ASCs)
 - clinical applications
 - bone reconstruction, 678
 - inflammatory disorders, 678–679
 - ischemic disorders, 679
 - soft tissue reconstruction, 675–678
 - differentiation, 672, 673
 - immunomodulatory properties, 674–675
 - paracrine function, 672–674
 - stromal-vascular fraction cells *vs.*, 670–672
- Adrenoleukodystrophy (ALD), 436
- Adventitial reticular cells, 92–93
- Amyotrophic lateral sclerosis (ALS), 515
- Angiopoietin-1 (Ang-1), 558
- Antigen-presenting cells (APCs), 463
- Asthma, 155
- Autoimmune disease (AD)
 - acute inflammatory, 510
 - autologous and allogeneic experiments, 511
 - CD44 glycoform, 512
 - E-selectin ligands, 511–512
 - human platelet lysate, 517

- Autoimmune disease (AD) (*cont.*)
 immunomodulatory mechanisms, 510–511
 MSCs and human experience
 anecdotal report, 515
 intrathecal infusion, 515
 SLE, 515
 SSc patients, 514
 therapeutic agents, 515, 516
 rodent models, 511
 tissue-protective effects
 acute lung injury murine model, 512
 cerebral ischaemia, 513
 CNS, 513
 immunosuppressive effect, 512
 ischaemia/reperfusion injury, 512
 retinal function, 513
 streptozotocin, 513–514
 vasculotropic effect, 512–513
- Autologous chondrocyte implantation (ACT), 665
- B**
- Bioluminescence imaging (BLI), 396
 Bladder regeneration, 250
 Bone marrow (BM), 495
 Bone marrow adipocytes, 99
 Bone marrow mononuclear cells (BMNC), 554
 Bone marrow transplantation (BMT), 53–54
- C**
- Calcineurin inhibitors (CNIs), 531
 Cardiac progenitor cells (CPC), 152
 Cardiovascular disease
 animal studies
 bone marrow-derived MSCs, 552
 clinical translation, 553
 large animal models, 549, 551
 small animal models, 548, 550
 weeks post-MI, 552–553
 biologic scaffolds, 559
 cell-based therapy, 548
 cell delivery methods
 advantages and disadvantages, 557, 558
 imaging methods, 557, 559
 clinical trials
 chronic ischemic cardiomyopathy, 555–556
 MI, 554–555
 observations, 557
 environmental conditions, 559
 gene modification, 558
 potential therapeutic mechanisms, 548, 549
- CD activity index (CDAI), 539–540
 Cell-assisted lipotransfer (CAL), 650
 Cell-based therapy, clinical trials
 in academic organizations, 285–286
 clinical protocol development
 elements, 303–305
 regulatory requirements for, 303
 resource needs for, 305–306
- CMC development
 alternative cell sources, 295
 alternative cryopreservation solutions, 295
 ancillary materials, 295–296
 assay development, 298–302
 biologic (donor-to-donor) variability, 293–294
 cell/tissue source, 293
 clinical protocol impact, 298
 collection method, 293–294
 density gradient step, 295
 DMSO, 297
 EBMT, 294
 excipient, 296–297
 fetal bovine serum (FBS) substitution, 295
 goal of, 292
 higher-risk materials, 296
 key considerations for, 292–293
 plastic bags, culture expansion, 295
 requirements, 292
 resource needs for, 302–303
 specifications, final product, 297
- IND development (*see* Investigational new drug (IND))
 investigational biological drugs, 284
 preclinical animal studies
 goals for, 289–290
 good laboratory practice, 290–291
 POC, 288
 resource needs for, 291
- project management and multidisciplinary teams
 drug and biologics development, 312–315
 project leader, 316
 stages, product life cycle, 312, 316
 quality and implementation issues
 cGMP and cGTP requirements, 310–311
 good clinical practice requirements, 307–309
 GxP, 306
 requirements for, 306
 resource needs for, 307, 310, 312
 regulatory affairs, 288

- CellSTACK, 333
- Center for International Blood and Marrow Transplant Research (CIBMTR), 455
- Central nervous system (CNS), 511
- cGMP production
- bone marrow, MSC isolation, 329–330
 - cell source
 - adipose tissue, 325
 - bone marrow, 324
 - donor evaluation, 325–326
 - umbilical cord blood, 325
 - culture method
 - aseptic processing qualification, 335
 - cell factories (Nunc), 333
 - CellSTACK, 333
 - cleanroom environment, 334
 - final formulation and cryopreservation, 333
 - process qualification, 334
 - FDA regulations and, 322–323
 - media selection
 - fetal bovine serum, 331
 - platelet lysates, 331–332
 - serum-free media, 332
 - process flow diagram, 327, 328
 - quality control testing (*see* Quality control testing)
 - raw materials, MSC production, 327–329
 - seed bank production, 330
- Chemical inducers of dimerization (CID), 386
- Chemistry, manufacturing, and control (CMC), 350
- alternative cell sources, 295
 - alternative cryopreservation solutions, 295
 - ancillary materials, 295–296
 - assay development, 298–302
 - biologic (donor-to-donor) variability, 293–294
 - cell/tissue source, 293
 - clinical protocol impact, 298
 - collection method, 293–294
 - density gradient step, 295
 - DMSO, 297
 - EBMT, 294
 - excipient, 296–297
 - fetal bovine serum (FBS) substitution, 295
 - goal of, 292
 - higher-risk materials, 296
 - key considerations for, 292–293
 - plastic bags, culture expansion, 295
 - requirements, 292
 - resource needs for, 302–303
 - specifications, final product, 297
- Chronic kidney disease (CKD), 607
- Clinical applications and European regulatory aspects
- marketing authorization, 361–362
- MSC-Based ATMPs
- biodistribution, 366
 - biomedicines, 361
 - characterisation/identity, 363–364
 - genetic stability, 366–367
 - microbiological and viral safety, 364
 - potency assays, 365
 - relevant nonclinical models, 365–366
 - small molecule medicinal products, 362
- CNIs. *See* Calcineurin inhibitors (CNIs)
- Colony-forming unit fibroblasts (CFU-F), 456
- Committee for Advanced Therapies (CAT), 360, 363
- Complete resolution (CR), 482
- Conditionally replicating adenoviruses (CRAds), 224
- Congestive heart failure (CHF), 555
- Coronary artery bypass grafting (CABG), 611
- Crohn's disease (CD), 517, 538
- Current good tissue practices (cGTP), 349
- Cutaneous wounds, 651
- Cyclosporine A (CsA), 481
- Cytotoxic T lymphocytes (CTLs), 418, 423
- D**
- Data safety and monitoring board (DSMB), 416
- Demineralized bone matrix (DBM), 80, 81
- Dendritic cells (DCs), 528
- Diabetes
- adipose tissue-derived MSCs, 591
 - anatomical site, 594
 - autoimmune diabetes
 - experimental rat model, 580
 - honeymoon period, 579
 - human bone marrow-derived MSCs, 580
 - NOD mice, 579
 - trophic mediators, 581
 - autologous cells, 593
 - blood sugar levels, 593
 - bone marrow-derived MSCs, 589–591
 - exocrine pancreas-derived MSCs, 589
 - immunosuppressive regimens, 578
 - inexhaustible source, 578
 - insulin-producing cells
 - b-cell potential, 587
 - induce b-cell differentiation, 585–587

- Diabetes (*cont.*)
 islet transplantation
 ADSC, 582
 allogeneic, 583
 anti-inflammatory effect, 582
 autologous, 583
 BM-derived cells, 583
 expansion and culture, 583–584
 MMP-2 and MMP-9, 582
 single agent/composite strategies, 584
 syngeneic marginal mass, 582
 xenogeneic, 583
 pancreatic islet-derived MSC, 587–588
 placenta, cord, and cord-blood tissues,
 592–593
 type 1 diabetes, 577
- Dimethyl sulfoxide (DMSO), 297
- E**
- Embryonic stem cells (ESCs), 372, 585
 Endorem[®], 404
 Endotoxin-induced lung injury, 155
 End-stage renal disease (ESRD), 606
 Engineered bone constructs, 655
 Engraftment, 441
 Epithelial-to-mesenchymal transition (EMT),
 214–215
 European group for blood and bone marrow
 transplantation (EBMT), 294
 Exosomal shuttle RNA (esRNA), 180
 Experimental autoimmune encephalomyelitis
 (EAE), 513
- F**
- Fat grafting, 650
 Feridex[®], 403–404
 Fetal bovine serum (FBS), 360, 387, 636
 Fetal calf serum (FCS), 613
 Fetal liver kinase-1 (FLK1), 512
 Fibrin glue, 652
 Fibroblast growth factor-2 (FGF-2), 558
 Fibroblastic reticular cells, 92
 Fluorescent-activated cell sorting (FACS), 364
 Food and drug administration (FDA), 400
- G**
- Gastrointestinal (GI) disorders
 biological and functional properties,
 538–539
 clinical application
 fistulizing Crohn's disease, 540–541
 liver cirrhosis, 541
 luminal Crohn's disease, 539–540
 MELD, 542
 immunosuppressive treatments, 543
 novel therapeutic strategy, 542
 paracrine mechanisms, 538
 regulatory T cells, 538
 in vivo animal models, 536–537
 Good manufacture practice (GMP), 636
 Graft-versus-host disease (GVHD), 423, 450
 chemoradiotherapy, 462
 clinical phenotype, 462
 clinical trials, 464–465
 donor T cells, 462
 immunomodulatory and reparative cells,
 465–466
 MSCs, 463–464
 murine models, 464
 standard therapy, 462–463
 Granulocyte colony-stimulating factor
 (G-CSF), 555
 Granulocyte-macrophage colony-stimulating
 factor (GM-CSF), 436
 Green fluorescent protein (GFP), 435
- H**
- Haematopoietic cell E-selectin/L-selectin
 ligand (HCELL), 512
 Hematopoiesis, 146–147
 Hematopoietic cell transplantation (HCT)
 biologic properties, MSCs, 451–452
 early studies, 452–453
 graft failure, treatment
 CMV infection, 457
 granulocyte colony-stimulating factor,
 457
 management strategies, 455
 pilot clinical trial, 456–457
 SAA, 456
 hematopoietic engraftment
 GVHD, 454–455
 hematologic malignancies, 454
 HPCs, 453
 UCB grafts, 454
 multipotent mesenchymal stromal cells,
 450–451
 myeloablative conditioning regimens, 450
 Hematopoietic progenitor cells (HPCs), 426
 Hematopoietic stem cell (HSC), 4, 18, 19,
 386, 492
 adventitial reticular cells, 92–93
 BM stroma, 92
 in bone marrow, 93–94

- bone marrow microenvironment:, 99–101
 - cellular components of
 - endothelial cells, 94–95
 - mesenchymal stem and osteoprogenitor cells, 95–96
 - osteoblasts, 94
 - direct cell contact, 93
 - fibroblastic reticular cells, 92
 - regulation of
 - bone marrow adipocytes, 99
 - bone marrow macrophages, 97–98
 - osteoclasts, 98–99
 - sympathetic neurons, 97
 - Hematopoietic stem cell transplantation (HSCT)
 - hereditary diseases, 474
 - HLA-identical donor, 474
 - immunomodulatory properties, 476–477
 - MSCs, 475–476
 - pediatric clinical studies
 - CD34+ cells, 479
 - inborn errors, metabolism, 478
 - refractory severe acute graft-versus-host disease, 481–483
 - T cell depletion, 478–479
 - UCB, 479–481
 - preclinical results, 477–478
 - Heme oxygenase-1 (HO-1), 558
 - Hepatocyte growth factor (HGF), 537, 558, 568
 - Herpes simplex virus (HSV), 401
 - High tibial osteotomies (HTO), 665
 - Hpatocyte growth factor (HGF), 581
 - Human leukocyte antigens (HLA), 462
 - Hurler syndrome, 437
- I**
- Immune cells, 136–137
 - Immune system, 174–176
 - dendritic cells, 174
 - natural killer (NK) cells, 174
 - nitric oxide (NO), 174
 - T cell proliferation, 173–174
 - Immunology, 442–444
 - Immunomodulatory property
 - autoimmune diseases and regenerative medicine, 119–121
 - B cells, 114
 - DCs, 114
 - ex vivo expansion, 108–109
 - graft-versus-host disease (GVHD), 118–119
 - HSC engraftment, 117–118
 - malignant transformation, safety data, 111
 - NK cells, 115
 - T cells, 113
 - tissue sources, clinical use, 110–111
 - in vitro, mechanism of action, 115–116
 - in vivo, mechanism of action, 121–122
- Inborn errors**
- clinical applications, 437
 - Hurler syndrome, 437
 - MLD, 438, 439
- OI**
- bone marrow, 439
 - clinical outcome, 442–444
 - COL1A1 and COL1A2, 438
 - engraftment, 441
 - growth-promoting effect, 444
 - immunology, 442–444
 - marrow mesenchymal cell processing, 441
 - mesenchymal cell therapy, 438–439
 - MSC transplantation, 441
 - type II and type III, 438
- therapeutic activity**
- bone/cartilage regeneration, 435
 - categories, 435
 - cross-correction, 435–436
 - immunohematology, 436
 - inflammatory response, 436–437
 - murine and human data, 436
 - pharmacologic therapies, 435
 - treatment, 436
- Inflammatory bowel disease (IBD), 536
 - Insulin growth factor-1 (IGF-1), 512
 - Interferon- γ (IFN- γ), 581, 674
 - International normalized ratio (INR), 542
 - International Society for Cellular Therapy (ISCT), 195, 451
 - International Society for Stem Cell Research (ISSCR), 375
 - Intervertebral disc repair, 250–251
 - Intravenous Stem Cells After Ischemic Stroke (ISIS), 634
 - Investigational new drug (IND)
 - applications
 - clinical trials, 351–352
 - CMC section, 351
 - FDA, 352
 - definition and contents, 286–287
 - regulatory process, 287–288
 - requirements, 286
 - In vivo imaging
 - MR imaging
 - clinical tracking trials, 403
 - Feridex[®]-labeled cells, 403–404
 - Kupffer cells, 404

- In vivo imaging (*cont.*)
 nephropathies, 403
 SPIO, 402–403
 T2-weighted images, 403–404
 noninvasive imaging, 397
 optical imaging
 bacterial luciferase, 397
 BLI, 396, 397
 bone marrow mononuclear cells,
 399–400
 D-luciferin, 397
 firefly luciferase, 397
 GFP fluorescence, 398
 human pancreatic carcinoma cells, 398
 renilla luciferase, 397
 tropism, 398, 399
 xenogeneic and syngeneic tumors, 398
 PET imaging, 401–402
 SPECT and nuclear imaging, 400–401
 Ischemic disorders, 679
 Ischemic stroke models, 625
- K**
 Keratinocyte growth factor (KGF), 568
 Kupffer cells, 404
- L**
 Leukemia cell homing, 215–217
- M**
 Macrophages
 CD206 positive M2 macrophages, 139
 classification, 138–139
 Magnetic resonance imaging (MRI), 557
 clinical tracking trials, 403
 Feridex[®]-labeled cells, 403–404
 Kupffer cells, 404
 nephropathies, 403
 SPIO, 402–403
 T2-weighted images, 403–404
 Major histocompatibility complex (MHC), 452
 Marketing authorisation application (MAA),
 360, 363
 Matrix metalloproteinases (MMP)-2 and 9,
 172, 582
 Maxillary sinus augmentation, 655
 Mesenchymal stem cells (MSCs)
 acute neurological disorders
 clinical variables, 636
 culture expansion, 636
 definition, lack of, 635–636
 source, 624–625
 spinal cord injury (*see* Spinal cord
 injury (SCI))
 standard translational questions, 636
 stroke (*see* Stroke)
 traumatic brain injury (*see* Traumatic
 brain injury (TBI))
 AD (*See* Autoimmune disease (AD))
 adipose tissue-derived, 202–203
 AKI (*See* Acute kidney injury (AKI))
 ALI (*See* Acute lung injury (ALI))
 angiogenesis, 178
 antimicrobial role, bone marrow, 137–138
 in autoimmune disorders and tissue repair,
 124–125
 β -catenin-mediated Wnt signaling, 180
 bone marrow transplantation, 53–54
 breast cancer tumor progression, 179–180
 cancer, 177–178
 characterization
 bone marrow vs. umbilical cord blood/
 adipose tissue, 195, 196
 Caplan MSC methods, 61
 cell junctions, 199–200
 cultivation techniques, 197–198
 culture media, 195, 197
 fibroblastic colony-forming units
 (CFU-F), 60–61
 gene expression profiling and
 proteomics, 198–199
 graft-versus-host disease incidence,
 cancer patient, 61–62
 intrinsic heterogeneity, 200–201
 isolation and immunophenotyping of,
 195
 spleen colony-forming units (CFU-Sp),
 60
 chemokine receptor CCR5, 180–181
 clinical applications
 in autoimmune disorders and tissue
 repair, 124–125
 engraftment, 122–123
 GVHD, 123–124
 clinical use of
 bioactive molecules, 86
 cellular events sequence, 85
 immunomodulation, 85
 trophic activity, 85–86
 in culture, 50–51
 demineralized bone matrix (DBM), 80, 81
 during embryonic development, 44, 45
 engraftment, 122–123
 esRNA, 180
 expressional lineages, 81

extracellular matrix
 matrix-degrading metalloenzymes, 172
 MMPs, 172
 TIMP, 172–173
 VBM, 171–172

fetal calf serum qualification, 63–64

flow cytometric analysis
 cell surface molecules, 65, 66
 expression levels, surface molecules, 66–67
 positive and negative markers, 65

fracture repair, 83–84

gene expression microarrays, 70

GI disorders (*See* Gastrointestinal (GI) disorders)

GVHD, 123–124

24-h incubation, 82, 83

with immune cells, 136–137

immune system, 174–176
 dendritic cells, 174
 natural killer (NK) cells, 174
 nitric oxide (NO), 174
 T cell proliferation, 173–174

immunologic properties, 497

immunomodulatory property
 autoimmune diseases and regenerative medicine, 119–121
 B cells, 114
 DCs, 114
 ex vivo expansion, 108–109
 graft-versus-host disease (GVHD), 118–119
 HSC engraftment, 117–118
 malignant transformation, safety data, 111
 NK cells, 115
 surface markers, 109–110
 T cells, 113
 tissue sources, clinical use, 110–111
 in vitro, mechanism of action, 115–116
 in vivo, mechanism of action, 121–122

macrophages, 138–139

mesenchyme, 46

mesengensis, 81, 82

microparticles and exosomes, 180

non-progenitor functions, 51–53

osteogenic cells isolation, 82

paracrine effects (*see* Paracrine effects)

pericytes, 84
 and pericytes, 48–49

perivascular bone marrow stromal cells, 47–48

population property, 70–73

potential areas, future study, 178–179

pro-inflammatory environment, 116–117
 in repairing tissues (*see* Repairing tissues)

skeletal tissues, 46–47

source tissues for, 63

stringent criteria, 49–50

stroma, 45–46

stromal support assay, 69–70

tissue-engineered restoration, 82

umbilical cord blood (UCB), 201–202

vasculature, 170–172

in vitro differentiation
 adipogenic, 67–68
 chondrogenic, 68
 osteogenic, 68–69

Mesengensis, 81, 82

Metachromatic leukodystrophy (MLD), 438

Microcalcification, 650

Minimal residual disease (MRD), 464

Mixed lymphocyte reactions (MLR), 674

Model for end-stage liver disease (MELD), 542

Modified Rankin Scale (mRS), 629

Monocyte chemotactic protein-1 (MCP-1), 512

Mononuclear cells (MNC), 493

Mycophenolate mofetil (MMF), 529

Myocardial infarction
 cardiac progenitor cells (CPC), 152
 neovascularization, 151
 tissue fibrosis, 152
 TNF- α IP6, 151
 ventricular remodeling, 151–152

Myocardial infarction (MI), 548, 554–555

N

National Cancer Institute (NCI), 426

National clinical trials (NCT), 420

National competent authorities (NCAs), 361

National heart, lung, and blood institute (NHLBI)
 bone marrow and cord blood, 410

PACT
 application process, 425–428
 origins of, 421–424

SCCT
 cell therapies, 420–421
 clinical activities, 418–420
 clinical trials, 415–416
 origins, 410–415
 research activities, 416–418
 research centers, 416, 417
 stem and progenitor cells, 409–410

Non-healing lower extremity ulcers, 652–653

Nonobese diabetic (NOD), 579

O

Optical imaging

- bacterial luciferase, 397
- BLI, 396, 397
- bone marrow mononuclear cells, 399–400
- D-luciferin, 397
- firefly luciferase, 397
- GFP fluorescence, 398
- human pancreatic carcinoma cells, 398
- renilla luciferase, 397
- tropism, 398, 399
- xenogeneic and syngeneic tumors, 398

Orthopedic surgery

- bone, 663
- cartilage
 - ACI, 665
 - cell-based therapies, 664
 - chronic knee pain, 666
 - femoral condyle, 664
 - HTO, 665
 - porous calcium hydroxyapatite sheet, 666
 - Staphylococcus aureus*, 666
- ligament and tendon, 663–664
- tissue engineering strategies, 662–663

Osteoblasts, 94

Osteoclasts, 98–99

Osteogenesis imperfecta (OI)

- bone marrow, 439
- clinical outcome, 442–444
- COL1A1 and COL1A2, 438
- engraftment, 441
- growth-promoting effect, 444
- immunology, 442–444
- marrow mesenchymal cell processing, 441
- mesenchymal cell therapy, 438–439
- MSC transplantation, 441
- type II and type III, 438

Osteonecrosis of femoral head (ONFH), 242

P

Paracrine effects

- diabetes, 156–157
- in hematopoiesis, 146–147
- in ischemic diseases
 - myocardial infarction, 150–152
 - stroke, 153–154
- in lung disease
 - asthma, 155
 - endotoxin-induced lung injury, 155
 - pulmonary fibrosis, 154–155
- MSC transcriptome
 - hypoxia, 149–150
 - mitogens secretion, 148

- rapid lineage specification, 148, 149
- toll-like receptors (TLRs), 149
- in neurodegenerative diseases, 157–158
- regeneration vs. replacement, 147–148
- in wound healing, 156

Parathyroid hormone (PTH), 418, 420

Parry–Romberg syndrome, 650–651

Pericytes, 84

Periodontal tissue engineering, 244–245

Perivascular bone marrow stromal cells, 47–48

Phytohemagglutinin (PHA), 674

Platelet lysate (PL), 476

Polymerase chain reaction (PCR), 477

Positron emission tomography (PET) imaging, 401–402

Pre-clinical large-animal models

- bladder regeneration, 250
- cardiac and coronary ischemia
 - canine models, 245–246
 - ruminant models, 246
- cell biology, tracking, and fate study
 - nonhuman primates, 252
 - pre-immune fetal sheep model, 251
- intervertebral disc repair, 250–251
- kidney disorders, ruminants, 249–250
- nervous system repair
 - canine models, 247–248
 - nonhuman primates, 248–249

orthopedic applications

- beta-TCP/HA matrix, 242–243
 - canine models, 238–239
 - cranial defects, sheep, 240
 - critical-size defects (CSDs), 240
 - massive allograft integration, 241
 - oral and maxillofacial surgery, 240
 - osteonecrosis of the femoral head (ONFH), 242
 - ovine split-mouth study, 240–241
 - partial-thickness lesions, sheep, 243
 - periodontal tissue regeneration, 240
 - tissue engineering approach, 243
 - triphasic ceramic-coated hydroxyapatite (HASi), 241
 - vertebral anatomy, 244
 - periodontal tissue engineering, 244–245
- Preclinical proof of concept (POC), 288
- Pre-immune fetus model
- fetal sheep model
- allogeneic/xenogeneic cells,
 - engraftment, 266
 - BM-derived, 268
 - circulating stem cells, homing, 265
 - donor-specific tolerance, 266
 - HEPAR-1 staining, 268
 - human hepatocytes (HePar), 267

- intraoperative (IP) transplantation, 268
 - reprogramming cellular fate, 265
 - MSC reprogramming
 - CFSE/DiD, 269
 - increased liver parenchyma, 269
 - Ki67 positivity, 269
 - mitochondrial transfer, donor cells, 270–271
 - Tau and/synaptophysin, 270
 - timeline determination, 269–270
 - tissue-specific cells, 270
 - in vitro* models, 262–263
 - in vivo* models, 263–265
 - Processed lipoaspirate (PLA), 670
 - Production assistance for cellular therapies (PACT)
 - application process
 - product manufacture, 426, 427
 - review criteria, 425
 - translational applications, 426, 428
 - origins of
 - clinical-grade manufacturing, 423
 - CTLs, 423
 - PACT cell processing centers, 424
 - recommendations, NHLBI, 422
 - stem cell transplantation, 421–422
 - Progenitor cell biology consortium (PCBC), 421
 - Pro-inflammatory environment, 116–117
 - Prostaglandin E2 (PGE2), 674
 - Protocol Review Committee (PRC), 416
 - Pseudomonas aeruginosa*, 572
 - Pulmonary arterial hypertension (PAH), 410
 - Pulmonary fibrosis, 154–155
- Q**
- Quality control testing
 - potency assays, 338–339
 - release testing
 - endotoxin, 337
 - identity testing, 335–336
 - karyotype, 338
 - microbial and fungal contamination, 337
 - MSC antigen expression, 337–338
 - mycoplasma, 337
 - residual FBS, 338
 - viable cell count, 336–337
- R**
- Reconstructive ladder, 646–647
 - Reconstructive surgery
 - composite reconstruction, 654–656
 - local cell injection, skin rejuvenation, 651
 - MSCs
 - ex vivo*-expanded, 649
 - functional mechanisms, 648, 649
 - reconstructive ladder, 646–647
 - soft tissue augmentation and scar, 650–651
 - tissue engineering, 654–656
 - wound healing, 651–654
 - Refractory severe acute graft-versus-host disease
 - complete resolution, 482
 - gastrointestinal tract, 483
 - methylprednisolone, 483
 - ransplant-related morbidity, 481–482
 - Regenerative medicine
 - anatomical location, MSC, 4
 - culture methodologies, 8–9
 - GVHD, 7
 - hematopoietic engraftment, 7
 - immunogenicity, 10
 - mechanism of action of, 5–6
 - murine models, 9–10
 - relevant animal model, 9
 - safety issues, 9
 - Repairing tissues
 - clonogenicity, 21
 - colony size, 21, 23
 - criterion of differentiation, 21, 22
 - engrafting and differentiating, 19–20
 - epitopes, 22
 - hematopoietic stem cells, 18, 19
 - immunomodulatory effects, 32–34
 - lung entrapment, 28–30
 - mitochondria transfer, 27–28
 - in non-mesenchymal cells
 - induced pluripotent stem cells, 24
 - neural cells and fibroblasts, 24
 - phase-contrast and fluorescence microscopy, 24, 26
 - stem cells differentiation, 24
 - Wnt and Notch signaling, 26–27
 - osteoblast and adipocyte differentiation, 21, 22
 - osteoblast-like mineralizing cells, 18
 - pericytes, 27
 - in rodent models, 30–31
 - transient cross-talk, 20
 - tumors, 34–35
 - universal donors, 31–32
 - Resovist®, 403, 404
- S**
- Safety issues
 - biological attributes, 389
 - clinical trial design, 389–391

- Safety issues (*cont.*)
 GVHD, 388
 immunosuppressive effect, 388
 risk factor
 cell culture risks, 387–388
 hematologic malignancies, 386–387
 intrinsic transformation, 384–385
 non-hematologic malignancies, 385–386
 tumorigenesis, 384
- Serial analysis of gene expression (SAGE), 148
- Single-photon emission computed tomography (SPECT), 401
- Sinus floor augmentation, 655
- Skin transplantation models, 529
- Small Business Innovation Research (SBIR), 411
- Small business technology transfer (STTR), 411
- Soft tissue augmentation and scar, 650–651
- Solid organ transplantation
 cellular immunotherapy, 531
 clinical trials, 531
 concurrent pharmacological
 immunosuppression, 530
 effective treatment, 526
 immunomodulatory and regenerative
 properties, 526–527
 preclinical models
 animal models, 529
 concurrent immunosuppression, role of,
 530
 skin transplantation models, 529
 transplant immunology and MSCs
 interfere, 527–528
- Specialized centers for cell-based therapy (SCCT)
 cell therapies, 420–421
 clinical trials, 418, 419
 CTLs, 418
 NHLBI expectations, 415–416
 origins of
 NHLBI's strategic planning process,
 411, 413–415
 PI, 411
 regenerative and reparative medicine,
 411, 412
 stem cell research, 411
 POSEIDON, 419–420
 PTH, 420
 research activities, 416–418
 research centers, 416, 417
- Spectral karyotyping (SKY), 367
- Spinal cord injury (SCI)
 cost, 624
 features, 624
 incidence of, 624
 methylprednisolone, 624
 MSCs
 cell delivery route, 626
 clinical trials, 634–635
 preclinical animal models, 625, 633
 therapeutic time window, 626–627
 trans-differentiation, 628
- Split-mouth fashion, 655
- Staphylococcus aureus*, 666
- Stem cell factor (SCF), 436
- Stem cell niche, 497
- Stem cell transplantation (SCT), 464
- Stem cell treatments
 allogeneic organs, 378
 clinics, 375
 HLA restrictions, 373
 HSCs, 372–373
 limitations, 372
 maverick physicians and entrepreneurial
 clinics, 376–377
 medical and scientific community, 378
 medical innovation, 375
 safe and effective therapies, 373, 374
 stem cell tourism, 375–376
 unregulation, 377
- Streptozotocin (STZ), 579
- Stroke, 153–154
 features, 624
 MSCs
 cell delivery route, 626
 clinical trials, 629, 634
 dosing, 627
 preclinical animal models, 625, 630–631
 therapeutic time window, 626–627
 trans-differentiation, 627
 tissue plasminogen activator, 623
- Stromal-derived factor-1 (SDF-1), 436, 511, 558
- Stromal-vascular fraction (SVF), 670–671
- Suicide gene therapy, 225
- Superparamagnetic iron oxides (SPIOs), 402
- Sympathetic neurons, 97
- Systemic lupus erythematosus (SLE), 484
- T**
- Transforming growth factor beta (TGF- β), 581
- Tissue inhibitors of metalloproteinases (TIMP), 172–173
- Total nucleated cell dose (TNC), 492
- Transplant-related mortality (TRM), 492
- Traumatic brain injury (TBI)
 deficits, 624
 features, 624

- MSCs
 - cell delivery route, 626
 - clinical trials, 635
 - dosing, 627
 - preclinical animal models, 625, 632
 - therapeutic time window, 626–627
 - trans-differentiation, 627
- Tropism, 398, 399
- Tumor-associated fibroblasts (TAFs), 212–213
- Tumor-associated macrophages (TAMs), 212–213
- Tumor microenvironment
 - EMT, 214–215
 - fibroblasts and stromal precursors, 217–218
 - leukemia cell homing
 - bone marrow (BM) microenvironment, 215
 - CXCR4 levels, 216–217
 - SDF-1, 216
 - sites of injury, 218–219
 - stroma role
 - BM microenvironment, components of, 213, 214
 - reciprocal-signaling partner, 212
 - TAFs, 212–213
 - TAMs, 212–213
 - target tumors
 - cellular vehicles, 220–222
 - stroma precursor cells, 219–221
 - therapeutic agents
 - CD44, 225–226
 - chemokines, 225
 - conditionally replicating adenoviruses (CRADs), 224
 - growth factor antagonist, 225
 - interferons, 223
 - interleukins, 223–224
 - lentiviral vectors, 224
 - retroviral transduction, 224
 - suicide gene therapy, 225
 - tumor-cell paradigm, cancer development, 210–211
- Tumor necrosis factor (TNF)- α , 572
- U**
- Umbilical cord blood (UCB), 201–202, 450
 - advantages, 480
 - bone marrow microenvironment, 495–497
 - CD34⁺ cells, 493
 - clinical trials, 493, 494
 - cord blood collection, 480
 - CsA, 481
 - graft contamination, 502
 - HSC, 492
 - immunologic properties, MSC, 497
 - liquid culture
 - bioreactors, 500–501
 - cytokines, 499
 - notch ligand, 500
 - tetraethylenepentamine, 499–500
 - MSC coculture, 497–498
 - myeloablative and non-myeloablative therapies, 492
 - progenitor cell, 501–502
 - stem cell niche, 497
 - transplantation, 479, 502
 - xenogeneic fetal sheep model, 493
- US**
 - regulatory perspective
 - GMP manufacturing, 352–353
 - IND application
 - clinical trials, 351–352
 - CMC section, 351
 - FDA, 352
 - manipulation, 348–349
 - MSC products
 - antimicrobial agents, 353–354
 - autologous serum, 354
 - cellular identity, 356
 - immunosuppressive activity, 355
 - malignant cells, 355
 - pooled serum, 354
 - principal investigator, 355–356
 - therapeutic regenerative medicine applications, 354
 - weak immunogenicity, 355
 - somatic cell therapies, 348
- V**
- Vascular basement membrane (VBM), 171–172
- Vascular endothelial growth factor (VEGF), 536–537, 558, 675
- Vasculature, 170–172